Cargando…
Nivolumab for Previously Treated Patients with Non-Small-Cell Lung Cancer—Daily Practice versus Clinical Trials
Based on the results of the CheckMate 017 and CheckMate 057 studies, nivolumab therapy has become a new standard treatment for both squamous and non-squamous non-small-cell lung cancer (NSCLC). However, due to the specific inclusion criteria of these clinical trials, the efficacy and safety of nivol...
Autores principales: | Knetki-Wróblewska, Magdalena, Kowalski, Dariusz M., Krzakowski, Maciej |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7408765/ https://www.ncbi.nlm.nih.gov/pubmed/32708936 http://dx.doi.org/10.3390/jcm9072273 |
Ejemplares similares
-
Nivolumab or Atezolizumab in the Second-Line Treatment of Advanced Non-Small Cell Lung Cancer? A Prognostic Index Based on Data from Daily Practice
por: Knetki-Wróblewska, Magdalena, et al.
Publicado: (2023) -
Efficacy of Immunotherapy in Second-Line Treatment of KRAS-Mutated Patients with Non-Small-Cell Lung Cancer—Data from Daily Practice
por: Knetki-Wróblewska, Magdalena, et al.
Publicado: (2022) -
Non-Small-Cell Lung Cancer Patients with Coexistence of High PD-L1 Expression and RET Fusion—Which Path Should We Follow? Case Reports and Literature Review
por: Knetki-Wróblewska, Magdalena, et al.
Publicado: (2022) -
Thymic epithelial tumors: Do we know all the prognostic factors?
por: Knetki‐Wróblewska, Magdalena, et al.
Publicado: (2021) -
Beta Blockers with Statins May Decrease All-Cause Mortality in Patients with Cardiovascular Diseases and Locally Advanced Unresectable Non-Small-Cell Lung Cancer after Chemoradiotherapy
por: Zaborowska-Szmit, Magdalena, et al.
Publicado: (2023)